心脏毒性
心力衰竭
医学
小桶
氧化应激
缬沙坦
MAPK/ERK通路
心肌病
药理学
炎症
心肌保护
射血分数
生物信息学
信号转导
癌症研究
内科学
心肌梗塞
基因
化疗
生物
转录组
细胞生物学
基因表达
血压
生物化学
作者
Hongwei Shi,Hao Lü,Yanlei Zheng,Peng Pu,Lai Wei,Desheng Hu,Heng Tang,Linlin Wang
标识
DOI:10.1016/j.bbrc.2023.149244
摘要
CRC is a common but serious complication or sequela of tumor treatment, and new coping strategies are urgently needed. SV is a classic clinical cardiovascular protective drug, which has been widely used in the treatment of heart failure, hypertension and other diseases. It has good therapeutic effect in other cardiovascular diseases such as diabetes cardiomyopathy, ischemic cardiomyopathy and vascular disease, but it has not been proved by research that SV can prevent and treat CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI